Table 1 summarizes the clinical statistics of the patient cohort. The MGMT promoter methylation analysis suggested that slightly more than half (51.4%) of the patients showed hyper-methylated MGMT promoter. Regarding MGMT genotyping, 29.2% tumors (21 of 72) carried the T allele at rs16906252, while only 18.2% (12 of 66) carried the same allele in control DNA. The allele frequency of the rs16906252 minor allele T in tumor samples was 15.3% and 9.8% in the matched-germline control samples. All relevant data of participant-level is summarized in S1 Table. The gene discussed is MGMT; the disease is neoplasm.